LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 114 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2024. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $164 | -31.4% | 165,394 | +2.5% | 0.00% | – |
| Q1 2024 | $239 | +139.0% | 161,314 | +77.5% | 0.00% | – |
| Q4 2023 | $100 | -1.0% | 90,896 | +6.5% | 0.00% | – |
| Q3 2023 | $101 | -16.5% | 85,336 | 0.0% | 0.00% | – |
| Q2 2023 | $121 | -9.7% | 85,336 | -4.2% | 0.00% | – |
| Q1 2023 | $134 | +28.8% | 89,100 | 0.0% | 0.00% | – |
| Q4 2022 | $104 | -99.9% | 89,100 | 0.0% | 0.00% | – |
| Q3 2022 | $101,000 | -11.4% | 89,100 | +23.1% | 0.00% | – |
| Q2 2022 | $114,000 | +21.3% | 72,400 | +18.5% | 0.00% | – |
| Q1 2022 | $94,000 | -34.3% | 61,091 | +4.6% | 0.00% | – |
| Q4 2021 | $143,000 | -51.0% | 58,391 | -49.5% | 0.00% | – |
| Q3 2021 | $292,000 | +90.8% | 115,691 | +115.3% | 0.00% | – |
| Q2 2021 | $153,000 | +48.5% | 53,731 | +22.7% | 0.00% | – |
| Q1 2021 | $103,000 | – | 43,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $52,403,228 | 3.69% |
| Raffles Associates | 1,536,946 | $2,305,419 | 3.14% |
| Defender Capital, LLC. | 5,136,085 | $7,704,128 | 2.69% |
| Prescott General Partners LLC | 1,851,851 | $2,777,777 | 0.22% |
| DAFNA Capital Management LLC | 140,000 | $210,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $67,500 | 0.05% |
| CTC Capital Management, LLC | 14,100 | $21,150 | 0.04% |
| Diametric Capital, LP | 50,875 | $76,313 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $1,172,649 | 0.03% |
| One68 Global Capital, LLC | 13,377 | $20,066 | 0.03% |